Last reviewed 2026-04-22 · How we verify

Adalimumab - GP2017

GP2017 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.

GP2017 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.

At a glance

Mechanism of action

As a TNF-α inhibitor, GP2017 blocks the interaction between TNF-α and its receptors on immune cells and tissue, thereby suppressing the inflammatory cascade. This mechanism is used to treat autoimmune and inflammatory conditions where TNF-α plays a pathogenic role. GP2017 is a biosimilar copy of the reference biologic adalimumab (Humira), designed to have equivalent efficacy and safety.

Approved indications

• Rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis
• Crohn's disease
• Ulcerative colitis
• Psoriasis
• Hidradenitis suppurativa

Common side effects

• Injection site reactions
• Upper respiratory tract infections
• Headache
• Serious infections (including tuberculosis)
• Malignancy risk

Key clinical trials

• Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) (PHASE3)
• Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis (PHASE3)
• Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Adalimumab - GP2017 CI brief — competitive landscape report
• Adalimumab - GP2017 updates RSS · CI watch RSS
• Sandoz portfolio CI